Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line

Trial ID # NCT01802749; MITO16B-MaNGO OV2B
Phase III
Drug Class Angiogenesis Inhibitors: VEGF
Drug Name Bevacizumab
Alternate Drug Names immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial Carboplatin, Liposomal doxorubicin, Paclitaxel, Bevacizumab, Gemcitabine
Eligible Participant

Platinum sensitive ovarian cancer after first-line treatment incl. bevacizumab (recurrence or progression either during or after bevacizumab as maintenance)

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Randomized


ORR, PFS, OS, evaluated per RECIST


CarboPt+Pac+Bev vs CarboPt+Pac:

ORR: 74.6 (20CR, 77PR) vs 65.7% (9CR, 85PR)
PFS: 11.8 vs 8.8 months, HR: 0.51 (0.41-0.65, p<0.001)
OS: 26.6 vs 27.1 months, HR: 0.97 (0.70-1.35, p=0.98, not mature)

Clinically Significant Adverse Events

CarboPt+Pac+Bev vs CarboPt+Pac:
Serious AE:
Grade 3-4 AE: hypertension (29 vs 10%)


Rechallenge with bevacizumab in combination with platinum-based doublets is associated with a significantly prolonged PFS


Pignata S et al. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trialMITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol (2018) 36 (suppl; abstr 5506)

Pignata S et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol (2021) 22(2):267-276

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.